185 related articles for article (PubMed ID: 29453769)
1. Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.
Del Mistro A; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Girlando S; Rizzolo R; Frayle H; Trevisan M; Sani C; Burroni E; Giorgi Rossi P; Cuzick J; Ronco G;
Int J Cancer; 2018 Jul; 143(2):333-342. PubMed ID: 29453769
[TBL] [Abstract][Full Text] [Related]
2. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
[TBL] [Abstract][Full Text] [Related]
3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
6. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
[TBL] [Abstract][Full Text] [Related]
7. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
8. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
9. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
10. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
11. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
[TBL] [Abstract][Full Text] [Related]
12. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
13. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
14. Human Papillomavirus Test for Triage of Japanese Women With Low-Grade Squamous Intraepithelial Lesions.
Iwata T; Hasegawa T; Ochiai K; Takizawa K; Umezawa S; Kuramoto H; Ohmura M; Kubushiro K; Arai H; Sakamoto M; Motoyama T; Watanabe K; Aoki D
Reprod Sci; 2015 Dec; 22(12):1509-15. PubMed ID: 26092278
[TBL] [Abstract][Full Text] [Related]
15. [Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen].
Liu ZH; Lin W; Wang YY; Wu B; Yuan SX; Yao JL; Zhao XS; Chen B; Qiao YL; Zhao FH; Chen W; Hu SY
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):757-763. PubMed ID: 30392340
[No Abstract] [Full Text] [Related]
16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
17. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
18. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study.
Wentzensen N; Wilson LE; Wheeler CM; Carreon JD; Gravitt PE; Schiffman M; Castle PE
Cancer Res; 2010 Nov; 70(21):8578-86. PubMed ID: 20959485
[TBL] [Abstract][Full Text] [Related]
19. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
20. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
Leeman A; Del Pino M; Molijn A; Rodriguez A; Torné A; de Koning M; Ordi J; van Kemenade F; Jenkins D; Quint W
BJOG; 2017 Aug; 124(9):1356-1363. PubMed ID: 28391609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]